We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

57 hedge funds and large institutions have $313M invested in Arcus Biosciences in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

14% more capital invested

Capital invested by funds: $274M → $313M (+$38.7M)

0.09% more ownership

Funds ownership: 50.38% → 50.47% (+0.09%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less funds holding

Funds holding: 64 → 57 (-7)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
57
Holders Change
-7
Holders Change %
-10.94%
% of All Funds
1.3%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
4
Increased
27
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$2.75M
2
Millennium Management
Millennium Management
New York
+$1.45M
3
BlackRock
BlackRock
New York
+$1.28M
4
BI
BVF Inc
California
+$1.26M
5
PIM
Platinum Investment Management
Australia
+$548K

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.26M
2
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$2.25M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.07M
4
LCM
Laurion Capital Management
New York
-$734K
5
PHS
PFM Health Sciences
California
-$567K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$70.4M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$61M -$321K -25,183 -0.6%
FCMI
3
Foresite Capital Management III
California
$48M – – –
EC
4
EcoR1 Capital
California
$31.2M – – –
BI
5
BVF Inc
California
$14.8M +$1.26M +99,000 +10%
HIM
6
Hillhouse Investment Management
Cayman Islands
$10.7M – – –
PHS
7
PFM Health Sciences
California
$10.1M -$567K -44,445 -6%
JP Morgan Chase
8
JP Morgan Chase
New York
$6.58M +$2.75M +215,534 +84%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$6.56M +$10K +787 +0.2%
Vanguard Group
10
Vanguard Group
Pennsylvania
$6.31M +$160K +12,511 +3%
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$6.26M -$2.25M -176,200 -28%
BlackRock
12
BlackRock
New York
$6.07M +$1.28M +100,154 +30%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$5.41M -$3.26M -255,700 -40%
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$4.24M +$115K +8,979 +3%
AG
15
Artal Group
Luxembourg
$4.18M – – –
FCMI
16
Foresite Capital Management IV
California
$4.11M – – –
VIA
17
Vident Investment Advisory
Georgia
$2.04M -$124K -9,755 -6%
Millennium Management
18
Millennium Management
New York
$1.97M +$1.45M +113,654 +414%
BBA
19
Baker Bros. Advisors
New York
$1.69M – – –
Northern Trust
20
Northern Trust
Illinois
$1.45M +$519K +40,735 +64%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.36M +$239K +18,748 +24%
PIM
22
Platinum Investment Management
Australia
$1.34M +$548K +43,000 +81%
State Street
23
State Street
Massachusetts
$1.25M +$321K +25,162 +39%
Fidelity International
24
Fidelity International
Bermuda
$743K – – –
MML Investors Services
25
MML Investors Services
Massachusetts
$720K +$445K +34,920 +209%
1
2 3

RCUS Hedge Fund Activity: Q3 2018 in Review

57 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q3 2018, worth a combined $313M — up 14% from $274M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of RCUS and 4 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 27 added.

The largest buyer was JP Morgan Chase, adding an estimated $2.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.26M.

  • 57 institutional investors held Arcus Biosciences (RCUS) as of Q3 2018, down from 64 in Q2 2018.
  • Funds reported $313M of Arcus Biosciences stock for Q3 2018, up 14% quarter-over-quarter.
  • 4 funds opened new Arcus Biosciences positions in Q3 2018 and 11 closed out, a net change of -7 holders.
  • The largest Arcus Biosciences buyer in Q3 2018 was JP Morgan Chase, an estimated $2.75M added.
  • The largest Arcus Biosciences seller in Q3 2018 was T. Rowe Price Associates, an estimated $3.26M sold.

Based on aggregated 13F filings for Q3 2018.